discov
christian
de
duve
lysosom
membranebound
vesicl
contain
numer
hydrolyt
enzym
break
biolog
polym
protein
lipid
nucleic
acid
lysosom
long
known
key
role
degrad
recycl
extracellular
materi
via
endocytosi
phagocytosi
intracellular
materi
via
autophagi
review
fig
product
lysosom
degrad
process
traffick
golgi
apparatu
reus
releas
cell
lysosom
exocytosi
import
immun
system
process
addit
becom
clear
recent
lysosom
import
role
cellular
process
includ
nutrient
sens
control
energi
fig
alter
lysosom
function
either
fusion
process
involv
gener
pathway
mention
relat
function
lysosom
enzym
nonenzymat
protein
result
broad
detriment
effect
includ
failur
clear
potenti
toxic
cellular
wast
inflamm
apoptosi
dysregul
cellular
defect
implic
mani
diseas
rang
rare
lysosom
storag
disord
lsd
caus
dysfunct
particular
lysosom
protein
common
autoimmun
neurodegen
despit
limit
impress
result
achiev
treat
sever
lsd
enzym
replac
therapi
ert
addit
substanti
effort
focus
therapeut
target
autophagi
process
upstream
howev
far
less
attent
investig
potenti
directli
target
lysosom
small
molecul
peptid
drug
nevertheless
recent
advanc
understand
lysosom
function
dysfunct
diseas
promis
novel
opportun
therapeut
intervent
target
lysosom
specif
begin
emerg
review
provid
brief
overview
lysosom
biogenesi
structur
function
describ
role
lysosom
dysfunct
lsd
well
common
diseas
specif
articl
focu
organspecif
nonorganspecif
autoimmun
diseas
includ
lupu
rheumatoid
arthriti
ra
multipl
sclerosi
ms
extens
review
elsewher
also
briefli
highlight
neurodegen
disord
alzheim
diseas
ad
parkinson
diseas
pd
illustr
breadth
natur
emerg
therapeut
opportun
current
toolbox
pharmacolog
agent
modul
lysosom
function
emerg
novel
target
strategi
set
indic
highlight
note
therapeut
approach
treat
inflammatori
autoimmun
diseas
aim
inhibit
deleteri
excess
lysosom
activ
wherea
lysosom
activ
would
goal
treatment
neurodegen
diseas
although
beyond
scope
review
approach
may
applic
diseas
lysosom
may
play
role
includ
cancer
metabol
diseas
age
review
format
matur
lysosom
complex
process
involv
fusion
late
endosom
contain
materi
taken
cell
surfac
transport
vesicl
bud
transgolgi
vesicl
contain
nearli
differ
hydrolyt
enzym
group
nucleas
proteas
phosphatas
lipas
sulfatas
other
synthes
endoplasm
reticulum
deliv
transport
vesicl
via
divers
system
tag
recogn
receptor
mpr
glucocerebrosidas
gcase
transport
lysosom
lysosom
integr
membran
ubiquit
express
type
iii
transmembran
glycoprotein
mainli
locat
endosom
matur
lysosom
acid
intern
ph
lysosom
hydrolas
activ
line
known
glycocalyx
protect
intern
lysosom
perimet
acid
environ
acid
environ
maintain
activ
vacuolartyp
proton
adenosin
triphosphatas
vatpas
har
energi
hydrolys
atp
drive
transloc
proton
membran
domain
review
key
lysosom
protein
includ
structur
protein
lysosomeassoci
membran
protein
protein
involv
traffick
fusion
solubl
nethylmaleimidesensit
factor
attach
protein
receptor
snare
rab
gtpase
transport
key
role
chaperonemedi
autophagi
cma
ion
channel
chlorid
channel
cation
channel
mucolipin
member
transient
receptor
potenti
trp
famili
also
known
protein
deliv
clathrin
adaptor
protein
phosphatas
alp
pathway
protein
transloc
lysosomeassociatedprotein
protein
preferenti
express
immun
although
concept
still
remain
controversi
two
lysosom
speci
convent
secretori
often
distinguish
base
physic
biochem
function
properti
catabol
main
function
convent
lysosom
sever
lysosomerel
organel
lro
melanosom
late
endosom
major
histocompat
complex
class
ii
mhcii
compart
miic
lytic
granul
neutrophil
eosinophil
basophil
mast
cell
cell
platelet
complement
mani
lro
act
profession
secretori
organel
lro
share
lysosom
major
typic
characterist
acid
environ
lysosom
transmembran
protein
fusion
properti
phagosom
other
addit
particular
properti
result
specif
cargo
exampl
melanosom
contain
melanosomespecif
transmembran
glycoprotein
natur
killer
cell
cell
contain
perforin
granzym
detail
mechan
biogenesi
secret
lro
remain
unclear
although
known
genet
defect
lro
involv
rare
autosom
recess
disord
character
reduc
pigment
diseas
secretori
lysosom
contain
mani
protein
addit
contain
convent
lysosom
particip
multipl
cell
function
plasma
membran
repair
tissu
bone
regener
apoptot
cell
death
cholesterol
homeostasi
pathogen
defenc
cell
lysosom
biogenesi
function
regul
basic
leucin
zipper
transcript
factor
eb
tfeb
coordin
lysosom
express
regul
clear
fig
exampl
autophagi
crucial
process
immun
transcript
regul
interestingli
lysosom
exocytosi
import
mani
immun
function
also
depend
tfeb
moreov
demonstr
tfeb
orchestr
lysosom
fact
multipl
lysosom
process
depend
tfeb
activ
strengthen
role
master
regul
lysosom
function
like
transcript
factor
tfeb
undergo
phosphoryl
dephosphoryl
via
differ
cytosol
lysosom
pathway
fig
process
regul
mechanist
target
rapamycin
complex
master
control
cell
lysosom
crossroad
variou
degrad
pathway
includ
endocytosi
phagocytosi
autophagi
fig
three
main
form
autophagi
describ
macroautophagi
extens
character
form
microautophagi
cma
initi
macroautophagi
doublemembran
sequest
compart
term
phagophor
contain
cytoplasm
materi
form
matur
vesicl
call
autophagosom
cargo
degrad
vacuol
issu
fusion
autophag
vesicl
lysosom
call
autolysosom
result
short
product
releas
back
cytosol
reus
accord
sometim
contest
observ
possibl
dispatch
miic
ultim
process
mhcii
molecul
load
present
contrast
macroautophagi
microautophagi
character
direct
lysosom
engulf
cytosol
materi
lysosom
via
format
characterist
invagin
lysosom
membran
third
major
form
autophagi
cma
involv
recognit
substrat
protein
contain
kferqlik
motif
complex
fig
cma
two
protein
key
role
ensur
select
protein
degrad
via
cma
pathway
transloc
target
cytosol
protein
across
lysosom
membran
review
termin
step
autophagi
call
autophag
lysosom
reform
tubular
protolysosom
extrud
autolysosom
contain
lysosom
membran
compon
matur
function
step
sole
lysosom
biogenesi
process
also
includ
seri
element
tightli
correl
regul
combin
autophagi
lysosom
involv
innat
adapt
immun
function
includ
foreign
materi
recognit
bacteri
parasit
viral
activ
pattern
recognit
receptor
tolllik
receptor
tlr
nucleotid
oligomer
domainlik
receptor
antigen
process
present
especi
context
mhcii
molecul
cell
homeostasi
antibodi
product
induct
variou
immun
signal
costimul
cytokin
secret
besid
degrad
organel
lysosom
recent
recogn
cellular
signal
play
import
role
nutrient
sens
addit
protein
complex
socal
lysosom
nutrient
sens
machineri
discoveri
stressinduc
lysosometonucleu
signal
mechan
tfeb
support
key
role
lysosom
cellular
lsd
heterogen
group
inherit
metabol
disord
incid
live
disord
treatment
review
extens
cover
rel
briefli
mutat
respons
lsd
larg
elucid
tabl
mani
result
dysfunct
particular
lysosom
hydrolas
lead
accumul
substrat
hydrolas
exampl
gaucher
diseas
sphingolipid
glucocerebrosid
accumul
cell
particularli
macrophag
organ
includ
liver
spleen
owe
defici
enzym
certain
lsd
result
patholog
explain
natur
molecul
accumul
tabl
thu
abund
cerebrosid
gangliosid
deposit
central
nervou
system
cn
patient
sphingolipid
storag
disord
type
ii
acut
infantil
neuronopath
gaucher
diseas
underli
sever
neurolog
symptom
patient
pomp
diseas
caus
defici
high
level
nondegrad
glycogen
accumul
muscl
could
explain
observ
howev
undegrad
materi
accumul
caus
observ
cellular
organ
patholog
mani
lsd
remain
unclear
accumul
undigest
macromolecul
monom
lsd
instig
format
secondari
product
ultim
escap
lead
multipl
consequ
affect
organ
includ
brain
liver
spleen
heart
eye
muscl
bone
tabl
organel
alter
lsd
includ
endosom
autophagosom
lysosom
function
lysosom
formationreform
fusion
endosom
autophagosom
lysosom
abnorm
alter
sever
autophagi
process
also
describ
lsd
thu
deregul
mitophagi
result
accumul
damag
mitochondria
occur
lsd
lead
major
inflammatori
consequ
specif
perturb
mitochondri
dynam
frequent
observ
link
increas
product
reactiv
oxygen
speci
atp
product
imbal
lsd
reduc
macroautophagi
activ
decreas
autophag
flux
rather
hyperact
autophagi
process
seen
numer
autoimmun
diseas
seem
respons
accumul
nondegrad
cytoplasm
protein
huntingtin
htt
mucolipidosi
type
iv
tabl
diseas
character
sever
neurolog
ophthalmolog
abnorm
caus
mutat
gene
inherit
autosom
recess
manner
gene
encod
nonselect
cation
channel
mucolipin
recent
shown
requir
effici
fusion
late
endosom
autophagosom
impair
autophagosom
degrad
result
accumul
autophagosom
microautophagi
process
involv
de
novo
synthesi
nascent
vacuol
also
appear
impair
lsd
notabl
reveal
primari
myoblast
patient
musclewast
condit
pomp
final
defect
cma
compon
could
also
lead
lysosom
dysfunct
exampl
mutat
gene
claim
caus
danon
diseas
inherit
xlink
domin
pattern
investig
need
support
assert
lysosom
involv
pathway
central
immun
system
includ
degrad
intracellular
extracellular
materi
plasma
membran
repair
cell
death
signal
cell
homeostasi
death
although
direct
involv
lysosom
immun
far
fulli
understood
long
expect
lysosom
dysfunct
major
impact
immun
diseas
tabl
strikingli
howev
field
extens
explor
howev
elev
level
lysosom
enzym
activ
report
occur
sever
autoimmun
diseas
ra
system
lupu
erythematosu
sle
dermatomyos
discuss
autophagosom
form
autophagi
process
must
fuse
lysosom
gener
peptid
epitop
process
clear
possibl
deleteri
apoptot
debri
fuel
amino
acid
pool
produc
energi
fig
deviat
complex
process
affect
crucial
immun
cell
function
control
cytokin
releas
autoimmun
cell
anergi
program
cell
death
type
apoptosi
type
ii
autophagi
secretori
lysosom
regul
releas
proinflammatori
antiinflammatori
cytokin
process
depend
type
stimul
addit
lysosom
degrad
glucocorticoid
receptor
essenti
bind
glucocorticoid
although
reason
complex
system
lysosom
execut
antiinflammatori
action
via
phospholipas
pathway
also
induc
inflamm
pathway
condit
proinflammatori
antiinflammatori
lysosom
act
indirect
precursor
autoimmun
howev
induct
suppress
inflammatori
signal
stimulu
lysosom
cathepsin
central
role
degrad
biolog
macromolecul
lysosom
immun
respons
approxim
member
larg
proteas
famili
endopeptidas
cleav
peptid
bond
protein
cathepsin
g
serin
proteas
cathepsin
e
aspart
proteas
cathepsin
b
c
f
h
k
l
v
x
w
cystein
proteas
exampl
cathepsin
respons
degrad
antigen
autoantigen
antigenpres
cell
dendrit
cell
macrophag
b
cell
therefor
involv
upstream
level
present
auto
antigen
peptid
complex
cathepsin
l
preferenti
cleav
peptid
bond
aromat
residu
posit
hydrophob
residu
posit
central
antigen
process
bone
resorpt
tumour
invas
metastasi
turnov
intracellular
secret
protein
involv
growth
regul
cathepsin
ldefici
mice
display
less
adipos
tissu
lower
serum
glucos
insulin
level
insulin
receptor
subunit
glucos
transport
type
fibronectin
wildtyp
cathepsin
g
primarili
known
function
kill
digest
engulf
also
involv
connect
tissu
remodel
site
antineutrophil
cytoplasm
antibodi
react
cathepsin
g
identifi
patient
abnorm
antigen
process
present
known
one
upstream
event
perturb
immun
respons
process
mediat
lysosom
ration
specul
lysosom
function
could
alter
lupu
interestingli
hypothes
rais
lysosom
fragil
lupu
without
much
composit
fluiditi
lysosom
membran
effect
crucial
regul
lysosom
fusion
vesicular
organel
lysosom
uptak
macromolecul
integr
lysosom
membran
also
ensur
prevent
releas
lysosom
enzym
cytoplasm
lysosom
enzym
releas
fragil
lysosom
regard
potenti
harm
lysosom
abnorm
splenic
b
cell
fasdefici
murphi
roth
larg
mrl
lpr
mice
mous
model
lupu
compar
b
cell
healthi
cbaj
tfeb
express
increas
indic
enhanc
biogenesi
lysosom
lysosom
volum
rais
express
level
cathepsin
also
increas
result
reinforc
previou
data
show
express
activ
lysosom
enzym
cathepsin
l
b
play
import
role
antigen
process
alter
lupu
autoimmun
substanti
variat
acid
endolysosom
ph
also
occur
mrllpr
mice
rais
ph
unit
splenic
b
ph
chang
could
dramat
influenc
activ
solubl
lysosom
hydrolas
cathepsin
well
lysosom
membran
protein
lamp
critic
lysosom
activ
ph
may
also
affect
elimin
immun
complex
accumul
lupu
result
deficit
complement
lower
express
scaveng
receptor
increas
express
receptor
immun
complex
contain
nonselect
igg
antibodi
autoantibodi
associ
autoantigen
includ
apoptot
debri
initi
inflamm
tissu
deposit
exampl
kidney
skin
gener
cascad
deleteri
effect
releas
harm
cytokin
recent
studi
highlight
key
role
mammalian
target
rapamycin
complex
disrupt
lysosom
acidif
occur
normal
condit
regul
lysosom
acidif
requir
cleavag
rab
small
gtpase
occur
surfac
phagocyt
vesicl
local
activ
fine
regul
process
requir
associ
cofilin
actin
surround
vesicl
recruit
activ
lupuspron
macrophag
chronic
activ
enhanc
cofilin
phosphoryl
therebi
hamper
associ
actin
affect
downstream
cascad
event
lead
appropri
acidif
import
establish
earlier
lupu
cell
particular
context
activ
increas
wherea
activ
addit
lysosom
cathepsin
k
seen
contribut
patholog
event
develop
faslpr
mice
anoth
model
lupu
diseas
part
activ
proteolyt
process
subsequ
effect
regulatori
cell
cathepsin
kdefici
faslpr
mice
reduc
kidney
patholog
manifest
glomerulu
tubulointerstiti
score
glomerulu
complement
fraction
igg
deposit
chemokin
express
macrophag
infiltr
decreas
level
potenti
pathogen
serum
line
intern
alter
lysosom
notabl
relat
cathepsin
function
deregul
autophagi
report
contribut
lupu
autophagi
failur
describ
lymphocyt
mrllpr
mice
nzbxnzw
two
spontan
murin
model
system
autoimmun
distinct
genet
origin
display
differ
mhc
haplotyp
well
b
lymphocyt
patient
murin
human
cell
peripher
blood
show
signific
accumul
autophag
vacuol
compar
underli
reason
dysfunct
autophagi
observ
lupu
clearli
understood
sever
independ
investig
identifi
risk
loci
span
autophagylink
gene
patient
recent
studi
demonstr
increas
level
macroautophagi
salivari
gland
lymphocyt
tear
conjunctiv
epitheli
cell
patient
primari
syndrom
sj
alter
cma
activ
also
recent
found
occur
salivari
gland
mrllpr
mice
develop
secondari
sjslike
lysosom
discuss
mechanist
involv
downstream
level
macroautophagi
cma
found
alter
salivari
gland
flow
cytometri
analys
reveal
mean
ph
acid
vesicl
mrllpr
salivari
gland
significantli
higher
compar
mous
control
gland
atp
content
significantli
diminish
mrllpr
salivari
gland
furthermor
amount
sever
leukocyt
glycosidas
proteas
reveal
increas
leukocyt
patient
sj
comparison
healthi
notabl
rais
level
lysosom
enzym
glucosidas
dipeptidyl
peptidas
involv
tissu
injuri
increas
express
lacrim
gland
cathepsin
also
report
may
applic
diagnost
tool
two
member
ra
oncogen
famili
found
implic
regul
cathepsin
secret
level
vitro
studi
lacrim
gland
acinar
cell
suggest
secret
acinar
cell
increas
cathepsin
express
stimul
mhciimedi
antigen
present
ocular
pathogenesi
lysosom
cathepsin
import
role
induct
diagnosi
ra
level
sever
cathepsin
b
g
k
l
present
serum
synovi
fluid
patient
propos
basi
ra
cathepsin
cathepsin
l
highli
express
synovi
macrophag
thymic
cortic
cell
exert
essenti
role
posit
select
cell
antigen
present
respect
particip
local
inflamm
matrix
degrad
occur
cathepsin
b
involv
collagen
degrad
lead
joint
destruct
express
cathepsin
g
particip
joint
inflamm
chemoattract
activ
shown
rais
synovi
fluid
patient
ra
compar
individu
autoantibodi
react
cathepsin
g
also
identifi
patient
compar
patient
osteoarthr
cathepsin
k
express
found
elev
genet
delet
particular
cathepsin
shown
reduc
inflamm
bone
eros
ra
condit
via
tlr
ms
myasthenia
gravi
syndrom
chronic
inflammatori
demyelin
polyneuropathi
cidp
neuromyel
optica
neuropsychiatr
lupu
neurolog
diseas
induc
abnorm
neurolog
autoimmun
variou
protein
myelin
ms
nmethyldaspart
receptor
neuropsychiatr
affect
variou
structur
within
cn
peripher
nervou
system
divers
consequ
although
exact
caus
amyotroph
later
sclerosi
al
still
remain
unknown
studi
support
exist
autoimmun
mechan
al
therefor
also
includ
section
inde
autoantibodi
gangliosid
sulfoglucuronylparaglobosid
neurofila
protein
voltageg
channel
report
patient
al
review
gener
origin
breakdown
immun
toler
occur
set
neurolog
diseas
known
recent
investig
discov
autophagi
process
alter
ms
experiment
autoimmun
encephalomyel
experiment
model
ms
upregul
protein
kinas
mtor
describ
treatment
rapamycinsirolimu
immunosuppress
inhibit
mtor
consequ
stimul
macroautophagi
amelior
clinic
histolog
sign
increas
level
macroautophagi
marker
measur
blood
brain
patient
howev
impair
macroautophagi
found
spinal
cord
experiment
autoimmun
encephalomyel
rat
model
mimick
human
cidp
macroautophagi
cma
process
found
hyperactiv
lymphat
system
cell
nonneuron
cell
sciatic
nerv
peripher
nervou
system
al
current
data
data
suggest
activ
macroautophagi
process
accumul
autophagosom
brain
tissu
patient
al
increas
autophag
vacuol
aggreg
ubiquitin
protein
associ
motor
neuron
mice
develop
alslik
contrast
data
suggest
reduct
autophagi
mutat
valosincontain
protein
dynactin
protein
complex
activ
dynein
motor
protein
enabl
intracellular
transport
member
small
gtpase
import
process
endosom
autophagosom
matur
also
describ
studi
requir
better
understand
type
extent
autophagi
dysfunct
famili
complex
diseas
publish
studi
lysosom
dysfunct
neurolog
autoimmun
diseas
tabl
notabl
includ
lysosom
fragil
observ
patient
ms
white
matter
cerebr
tissu
area
cn
mainli
made
myelin
lysosom
fragil
also
suspect
sle
see
rheumat
autoimmun
diseas
albeit
note
signific
variat
lysosom
ph
measur
autoimmun
condit
lupu
sj
knowledg
studi
conduct
brain
element
peripher
nervou
system
patient
anim
model
neurolog
autoimmun
diseas
cidp
shown
schwann
cell
dedifferenti
immatur
state
dedifferenti
cell
activ
lysosom
proteasom
protein
degrad
base
observ
schwann
cell
claim
activ
particip
demyelin
process
via
dedifferenti
process
mechan
involv
remain
rat
model
cidp
mention
shown
express
drastic
increas
sciatic
nerv
macrophag
reduc
macroautophagi
observ
schwann
cell
ms
studi
conduct
white
matter
demonstr
lysosom
involv
myelin
sheath
degener
well
fragment
protein
format
lysosom
swell
observ
near
degener
materi
accumul
lipid
hypothes
lysosom
swellingpermeabil
might
caus
releas
hydrolas
cytosol
affect
nativ
al
patient
also
show
dysfunct
endolysosom
pathway
affect
lower
upper
motor
neuron
tabl
cathepsin
b
particularli
found
involv
motor
neuron
degener
wherea
cathepsin
h
l
significantli
cdna
microarray
analysi
postmortem
spinal
cord
specimen
four
sporad
patient
al
reveal
major
chang
express
mrna
gene
includ
increas
express
cathepsin
b
sever
diseasecaus
mutat
gene
relat
autophagi
identifi
fu
optn
none
code
lysosom
protein
crucial
remain
issu
clearli
determin
whether
lysosom
abnorm
observ
link
intrins
default
lysosom
result
upstream
dysregul
autophagosom
format
insuffici
clearanc
neurotox
protein
network
implic
numer
neurodegen
disord
ad
huntington
diseas
hd
pd
modifi
misfold
protein
abnorm
accumul
specif
region
brain
accumul
aggreg
protein
also
seen
al
see
abnorm
protein
form
deposit
intracellular
inclus
extracellular
aggreg
characterist
although
substanti
research
field
still
unclear
sophist
qualitycontrol
system
system
particular
fail
certain
circumst
protect
brain
protein
ad
one
common
neurodegen
disord
alter
endolysosom
pathway
describ
review
amyloid
precursor
protein
app
cleav
peptid
fragment
particularli
fragment
found
amyloid
plaqu
one
hallmark
ad
neurofibrillari
tangl
contain
phosphoryl
tau
wide
consid
import
role
ad
cellbas
experi
demonstr
lysosom
cathepsin
role
gener
peptid
cathepsin
e
degrad
peptid
cathepsin
b
lysosom
dysfunct
observ
patient
accumul
fragment
neuron
cell
shown
lead
lysosom
membran
alter
caus
neuron
cell
context
noteworthi
inhibit
cathepsin
involv
lysosom
dysfunct
notabl
cleavag
tau
protein
tanglelik
fragment
diminish
hyperphosphoryl
brain
patient
addit
patient
ad
inherit
form
diseas
may
carri
mutat
presenilin
protein
app
apolipoprotein
e
result
increas
product
longer
form
fragment
review
mutat
instanc
lead
direct
disrupt
lysosom
acidif
due
impair
deliveri
subunit
vatpas
proton
pump
respons
control
intracellular
extracellular
ph
cell
acidif
deficit
caus
excess
releas
lysosom
channel
numer
deleteri
find
strongli
support
hypothesi
dysfunct
endolysosom
pathway
pivot
ad
approxim
patient
pd
famili
histori
disord
although
underli
molecular
mechan
remain
unclear
context
lysosom
dysfunct
notabl
common
known
pd
genet
mutat
encod
lysosom
gene
underli
gaucher
diseas
present
patient
pd
unit
mutat
also
associ
dementia
lewi
sever
gene
link
pd
directli
indirectli
relat
endolysosom
machineri
mutat
snca
code
hallmark
pd
presenc
neuron
protein
inclus
call
lewi
bodi
mainli
compos
fibrillar
protein
normal
degrad
lysosom
cma
pathway
macroaggreg
mutant
display
longer
halflif
compar
nonaggreg
wildtyp
protein
degrad
pathway
rather
would
degrad
via
macroautophagi
shown
mutant
protein
bind
inhibit
transloc
substrat
therefor
final
biochem
analys
suggest
mainli
degrad
lysosom
proteas
notabl
cathepsin
rather
nonlysosom
proteas
exampl
calpain
accumul
observ
cathepsin
ddefici
mice
wherea
convers
accumul
aggreg
reduc
transgen
mice
overexpress
cathepsin
result
protect
dopaminerg
neuron
cell
hd
rare
autosomaldomin
neurodegen
diseas
caus
aberr
expans
cag
trinucleotid
repeat
within
exon
htt
gene
result
product
aggregationpron
htt
mutant
mhtt
detriment
wherea
htt
protect
role
neuron
apoptosi
accumul
mhtt
howev
induc
pathophysiolog
consequ
includ
lysosom
autophagi
dysfunct
thu
mhtt
perturb
postgolgi
traffick
lysosom
compart
deloc
complex
turn
affect
lysosom
excess
mhtt
induc
accumul
clathrin
adaptor
complex
golgi
increas
clathrinco
vesicl
vicin
golgi
activ
sever
cathepsin
b
e
l
z
also
link
cathepsin
respons
full
degrad
htt
less
effici
degrad
mhtt
process
cathepsin
cathepsin
z
also
cleav
htt
elong
polyglutamin
thu
lysosom
modul
act
cathepsin
activ
might
benefici
effect
treatment
hd
notabl
hyperexpress
cathepsin
cathepsin
b
shown
protect
primari
neuron
mhtt
alter
macroautophagi
mitophagi
cma
also
implic
cma
activ
increas
respons
macroautophagi
failur
earli
stage
result
support
find
import
role
clearanc
shrnamedi
silenc
increas
aggreg
studi
focus
htt
secretori
pathway
reveal
mhtt
secret
mediat
lysosom
exostosi
mechan
via
synaptotagmin
sensor
extracellular
releas
mhtt
effici
inhibit
phosphoinositid
sphingomyelinas
inhibitor
hddepend
perinuclear
local
lysosom
also
increas
evid
thu
implic
lysosom
autophagi
dysfunct
pathogenesi
neurodegen
tfeb
receiv
particular
attent
recent
data
suggest
tfeb
select
lost
patient
ad
well
al
increas
tfeb
activ
might
therefor
prevent
neuron
death
restor
neuron
function
certain
neurodegen
diseas
includ
addit
ert
lsd
box
drug
discoveri
programm
also
focus
altern
small
moleculebas
approach
may
particularli
relev
lsd
affect
cn
due
lack
barrier
penetr
small
molecul
use
substrat
reduct
therapi
prevent
accumul
substrat
defect
enzym
lsd
inhibit
enzym
involv
substrat
miglustat
first
drug
approv
earli
us
food
drug
administr
european
medicin
agenc
gaucher
diseas
diseas
type
c
europ
iminosugar
inhibit
glucosylceramid
synthas
gc
catalys
initi
step
format
mani
glycosphingolipid
within
cell
glycosphingolipid
tend
local
outer
leaflet
plasma
membran
cycl
within
cell
endocyt
pathway
involv
lysosom
inhibit
gc
therefor
reduc
deleteri
accumul
glycosphingolipid
within
lysosom
potenti
therapeut
benefit
diseas
like
lsd
miglustat
also
inhibit
disaccharidas
gastrointestin
tract
result
diarrhoea
side
eliglustat
anoth
gc
inhibitor
penetr
cn
also
approv
gaucher
diseas
gc
inhibitor
clinic
develop
includ
lucerastat
miglustat
analogu
improv
safeti
profil
current
phase
iii
trial
fabri
diseas
fd
ibiglustat
penetr
cn
latter
clinic
develop
fd
phase
ii
gaucher
diseas
type
phase
ii
patient
pd
carri
mutat
gba
phase
ii
recent
find
gener
small
number
patient
suggest
possibl
link
pd
also
exist
patient
pd
gaucher
diseas
gba
mutat
see
final
genistein
pleotrop
natur
product
inhibit
kinas
involv
regul
proteoglycan
biosynthesi
also
affect
tfeb
function
phase
iii
trial
sanfilippo
substrat
mimet
inhibit
lysosom
enzym
also
found
stabil
mutat
enzym
lsd
therebi
lead
restor
enzym
activ
suitabl
subinhibitori
concentr
use
enzym
remain
stabl
function
dissoci
pioneer
exampl
approach
migalastat
describ
bind
activ
site
mutat
fd
stabil
mutant
enzym
exampl
strategi
includ
afegostat
gaucher
diseas
fail
phase
ii
clinic
trial
due
lack
efficaci
pyrimethamin
sandhoff
diseas
diseas
ambroxol
gaucher
diseas
neurolog
symptom
tabl
agent
earlier
development
stage
includ
competit
inhibitor
gaucher
diseas
nacetylcystein
pomp
diseas
azasugar
krabb
diseas
indic
chemic
structur
pharmacolog
chaperon
describ
final
altern
strategi
stabil
mutant
enzym
bind
away
activ
site
also
investig
promis
exampl
approach
noninhibitori
smallmolecul
chaperon
gcase
discov
screen
molecul
improv
activ
mutant
treatment
reduc
lysosom
substrat
storag
level
dopaminerg
neuron
deriv
induc
pluripot
stem
cell
patient
gaucher
diseas
test
patient
pd
gba
mutat
await
although
promis
conflict
viewpoint
still
remain
strength
small
moleculebas
approach
primarili
compound
bind
catalyt
site
enzym
may
risk
high
concentr
inhibit
rather
increas
clinic
trial
therefor
requir
order
analys
robust
approach
robust
genet
pharmacolog
preclin
investig
consist
show
regul
cathepsin
activ
favour
improv
patholog
featur
certain
autoimmun
inflammatori
diseas
inhibitor
sever
cathepsin
b
l
k
activ
evalu
rheumat
autoimmun
diseas
sle
ra
sj
neurodegen
disord
notabl
tabl
select
inhibit
cathepsin
potent
activ
site
inhibitor
known
roch
mitig
diseas
mrllpr
lupuspron
mice
reduc
prime
b
cell
dendrit
cell
plasma
cell
promis
data
also
gener
murin
model
context
diabet
nephropathi
cardiovascular
studi
base
cathepsin
inhibitor
evalu
clinic
safeti
util
treat
patient
affect
autoimmun
inflammatori
cathepsin
k
highli
express
osteoclast
effici
degrad
type
collagen
major
compon
organ
bone
matrix
also
potenti
target
modul
lysosom
dysfunct
disord
discuss
yet
investig
select
cathepsin
k
inhibitor
requir
determin
whether
target
strategi
might
appli
sle
inflammatori
condit
articular
manifest
major
compon
ra
ankylos
spondyl
psoriat
arthriti
other
note
howev
variou
cathepsin
k
inhibitor
pursu
postmenopaus
osteoporosi
includ
odanacatib
merck
reach
phase
iii
although
odanacatib
effect
develop
discontinu
due
increas
risk
stroke
treat
patient
cathepsin
inhibitor
context
clinic
evalu
list
tabl
despit
multipl
effort
develop
select
pharmacolog
cathepsin
modul
import
concern
still
remain
regard
offtarget
effect
due
activ
cathepsin
toward
cathepsin
present
nonrelev
unwant
site
nonetheless
underli
biolog
clinic
effect
certain
cathepsin
inhibitor
activ
remain
consider
interest
could
guid
futur
therapeut
approach
report
vatpas
multisubunit
atpdriven
proton
pump
best
known
role
acidif
endosom
lysosom
regul
function
vatpas
may
impact
lysosom
activ
henc
acidif
special
cell
divers
signal
pathway
autophagi
vatpas
inhibitor
like
bafilomycin
concanamycin
nonselect
compound
tabl
fig
inhibit
mammalian
nonmammalian
vatpas
control
lysosom
ph
acid
vesicl
via
manner
fulli
understood
fig
mechan
bafilomycin
inhibit
autophag
flux
prevent
acidif
endosom
bafilomycin
cq
also
affect
mitochondri
function
discov
recent
use
intact
benzolactoneenamid
salicylihalamid
lobatamid
oximidin
tabl
fig
much
select
vatpas
bafilomycin
concanamycin
also
much
less
potent
investig
vatpas
regul
signal
pathway
need
identifi
specif
safe
molecul
regul
vital
proton
discuss
lysosom
ion
channel
master
element
lysosom
activ
therebi
cell
homeostasi
famili
trp
channel
essenti
wide
express
late
endosom
lysosom
preferenti
associ
lysosom
genet
mutat
lead
inactiv
caus
rare
genet
disord
call
mucolipidosi
type
iv
mliv
pharmacolog
activ
amelior
lysosom
function
classic
associ
mliv
npc
certain
lsd
tabl
fig
thu
small
molecul
fig
identifi
screen
activ
defin
activ
display
addit
effect
combin
endogen
activ
ptdin
analogu
chlorin
thiophen
replac
methyl
group
show
greater
efficaci
anoth
molecul
call
fig
act
mucolipin
synthet
agonist
also
show
addit
effect
endogen
ptdin
import
note
neurolog
diseas
well
indic
lysosom
acidif
defect
see
interf
may
contraind
central
modul
lysosom
lipid
kinas
fyve
fingercontain
phosphoinositid
kinas
pikfyv
convert
ptdin
latter
regul
releas
lysosom
lumen
requir
acidif
vatpas
inactiv
pikfyv
lead
mani
pathophysiolog
problem
includ
neurodegener
immun
dysfunct
mostli
relat
impair
autophag
flux
alter
lysosom
traffick
transport
biogenesi
swell
smallmolecul
apilimod
fig
tabl
origin
identifi
inhibitor
tlrinduc
later
found
highli
specif
inhibitor
apilimod
evalu
clinic
trial
involv
sever
hundr
patient
helper
helper
cellmedi
inflammatori
diseas
crohn
diseas
ra
well
toler
human
subject
normal
healthi
volunt
patient
inflammatori
diseas
clinic
trial
meet
primari
endpoint
develop
abandon
apilimod
current
evalu
clinic
trial
aim
defin
maximum
toler
dose
patient
b
cell
nonhodgkin
lymphoma
monitor
safeti
pharmacokinet
pharmacodynam
preliminari
anoth
select
inhibitor
pikfyv
tabl
fig
inhibitor
contain
fyvetyp
zinc
finger
domain
found
significantli
reduc
surviv
primari
mous
hippocamp
neuron
cultur
revers
impair
endosom
traffick
cell
mimick
effect
produc
deplet
pikfyv
small
interf
rna
also
found
block
retrovir
exit
bud
clinic
perspect
although
target
pikfyv
highli
promis
work
requir
pave
way
toward
futur
treatment
sever
molecul
farnesyl
transferas
inhibitori
activ
develop
howev
earlier
compound
found
major
side
effect
develop
discontinu
lonafarnib
eiger
biopharmaceut
synthet
tricycl
halogen
carboxamid
recent
shown
promis
transgen
mous
express
human
tau
carri
tabl
mice
develop
tangl
hippocampu
amygdala
entorhin
cortex
cerebr
cortex
week
hippocamp
neuron
die
week
compar
untreat
mice
mice
receiv
lonafarnib
display
less
abnorm
behaviour
half
tangl
hippocampi
cortic
treatment
also
prevent
brain
atrophi
typic
occur
transgen
mice
reduc
microgliosi
hippocampu
temper
astrogliosi
cortex
mechanist
studi
shown
lonafarnibtr
mice
substrat
effici
deliv
lysosom
degrad
product
disappear
faster
organel
readili
degrad
specif
improv
lysosom
effici
know
lonafarnib
alreadi
approv
use
human
indic
cancer
ongo
evalu
progeria
hepat
delta
viru
infect
might
therefor
repurpos
use
patient
tauopathi
class
farnesyl
transferas
inhibitor
tipifarnib
johnson
johnson
might
also
display
interest
therapeut
properti
seen
block
lysosomaldepend
degrad
bortezomibinduc
aggresom
without
inhibit
earli
step
autophagi
kuraoncolog
inlicenc
tipifarnib
molecul
target
chaperon
protein
involv
lysosom
function
also
design
potenti
therapeut
applic
one
molecul
smallmolecul
inhibitor
key
element
bind
nucleotid
bind
domain
act
atpcompetit
inhibitor
atpas
chaperon
activ
mous
model
ad
mice
intraperiton
treatment
reduc
two
main
patholog
featur
ad
amyloid
plaqu
pair
helic
filament
tau
accumul
improv
object
recognit
locat
episodiclik
anoth
molecul
phosphopeptid
tabl
fig
also
shown
interact
fig
lodg
nucleotid
bind
howev
mechan
action
effect
phosphoryl
analogu
nomin
peptid
initi
spot
cellular
screen
assay
use
overlap
peptid
cover
whole
spliceosom
protein
cell
collect
lymph
node
lupuspron
mrllpr
peptid
enter
b
cell
via
clathrin
coatdepend
endocytosi
process
reach
earli
endosom
late
affect
cma
hyperactiv
lupu
like
hamper
cmamedi
chaperon
peptid
reduc
excess
express
observ
lupu
mice
alter
auto
antigen
present
mhcii
molecul
miic
compart
consequ
attenu
activ
autoreact
signific
diminut
mhc
molecul
express
surfac
antigenpres
cell
measur
mice
receiv
peptid
intraven
patient
peripher
cell
treat
ex
vivo
downstream
consequ
activ
autoreact
b
cell
differenti
autoantibodysecret
cell
cell
patient
lupu
longer
respond
ex
vivo
peptid
encompass
cell
effect
cma
demonstr
vitro
use
fibroblast
cell
line
stabli
express
cma
select
target
cmalysosom
process
effect
evalu
murin
model
mimick
rheumat
diseas
promis
result
notabl
mice
develop
sj
mice
neuropsychiatr
lupu
rat
develop
cidplik
diseas
disturb
cma
macroautophagi
sciatic
clinic
trial
includ
patient
sle
formul
mannitol
found
safe
nonimmunogen
sever
subcutan
administr
show
signific
efficaci
multicentr
doubleblind
phase
ii
peptid
current
evalu
phase
iii
trial
unit
state
europ
mauritiu
continu
openlabel
trial
includ
sever
hundr
patient
lupu
worldwid
plan
anoth
peptid
discov
contrast
activ
peptid
call
humanin
origin
identifi
surviv
neuron
patient
ad
found
directli
enhanc
cma
activ
increas
substrat
bind
transloc
lysosom
humanin
interact
stabil
bind
chaperon
cma
cargo
bind
lysosom
membran
result
import
humanin
shown
possess
cardioprotect
neuroprotect
properti
diseas
ad
cardiovascular
diseas
stroke
myocardi
infarct
diabet
addit
target
discuss
emerg
potenti
lysosom
therapeut
target
strong
biolog
valid
yet
small
molecul
develop
target
exampl
like
pharmacolog
tractabl
lysosom
k
channel
call
import
maintain
membran
potenti
ph
stabil
defici
may
play
critic
role
pd
importantli
structur
recent
anoth
target
ligand
yet
valid
channel
also
name
mchannel
channel
shown
diseas
reduc
cholesterol
efflux
lysosom
aberrantli
modifi
neuron
fire
disrupt
lysosom
cholesterol
efflux
decreas
ptdin
channel
activ
may
lead
aberr
neuron
activ
cholesterol
transport
ptdin
floppas
respons
declin
ptdin
consequ
modifi
electr
properti
diseas
neuron
dysfunct
activ
alter
level
ptdin
due
notabl
genet
mutat
might
also
involv
neuropathi
exampl
form
epilepsi
hd
pd
ad
al
friedrich
ataxia
although
experi
need
valid
link
discov
hyperexcit
cell
death
diseas
neurodegen
diseas
small
molecul
retigabin
anticonvuls
drug
keep
channel
open
might
repres
import
therapeut
channel
open
ligand
includ
deriv
anoth
promis
therapeut
target
sphingomyelin
phosphodiesteras
defect
gene
encod
caus
diseas
type
type
b
convert
sphingomyelin
ceramid
also
phospholipas
c
activ
reduc
activ
acid
sphingomyelinas
associ
mark
decreas
lysosom
stabil
describ
patient
diseas
phenotyp
correct
treat
cell
recombin
final
specif
lysosom
protein
display
decis
role
cma
shown
overexpress
certain
patholog
set
certain
cancer
inflammatori
diseas
autoimmun
nonautoimmun
downregul
express
might
therapeut
mention
howev
indic
defect
latter
due
reduc
stabil
cma
receptor
decreas
de
novo
synthesi
exampl
age
result
aggreg
lysosom
membran
pathogen
protein
ubiquitin
carboxytermin
hydrolas
deubiquitin
enzym
mutant
tau
known
amass
neurodegen
disord
see
target
therefor
remain
challeng
although
sever
strategi
may
envisag
exampl
control
de
novo
synthesi
hamper
multimer
lysosom
possibl
via
andor
chaperon
regul
degrad
rate
monom
reus
lysosom
current
research
lysosom
function
dysfunct
reveal
novel
role
lysosom
diseas
pathogenesi
highlight
new
opportun
treat
lysosom
autophagyrel
diseas
case
autophagi
lysosom
activ
inhibit
must
investig
caution
lysosom
activ
abnorm
reduc
enhanc
organ
tissu
other
anoth
scale
lysosom
activ
alter
certain
lysosom
other
within
cell
biodistribut
studi
vivo
must
undertaken
avoid
accumul
pharmaceut
healthi
organ
tissu
obviou
requir
safeti
ensur
drug
use
lysosom
modul
particular
type
lysosom
diseas
increas
vulner
anoth
diseas
still
much
learn
intim
work
lysosom
due
abund
constitut
element
compris
vesicl
ad
complex
result
plastic
ion
channel
transport
acidif
swell
vast
amount
protein
peptid
transloc
lysosom
digest
lytic
enzym
sensit
analysi
method
allow
import
inform
gener
lysosom
membran
protein
larg
major
howev
mani
question
remain
relat
express
regul
regul
transloc
chaperon
activ
exampl
certain
cell
contain
socal
secretori
lysosom
cytotox
cell
wherea
cell
subset
contain
convent
secretori
lysosom
platelet
consid
larg
famili
endolysosom
vesicl
whole
notion
secretori
convent
lysosom
remain
matter
debat
mani
instanc
lysosom
act
basal
cell
metabol
organel
wherea
case
assist
regul
homeostasi
unconvent
secretori
pathway
known
lysosom
exocytosi
differ
signal
mechan
although
sever
assay
use
measur
activ
lysosom
valid
worldwid
box
tabl
limit
includ
issu
associ
reliabl
perform
sensit
notabl
vivo
anoth
level
complex
come
inher
organel
heterogen
issu
tremend
import
unfortun
tool
equip
hand
today
virtual
imposs
examin
happen
lysosom
individu
patient
introduct
microfluid
singlecel
analysi
technolog
enabl
cellular
popul
character
huge
advanc
perform
howev
level
precis
yet
achiev
level
lysosom
know
lysosom
heterogen
natur
composit
activ
even
normal
set
equal
compet
autophagi
type
activ
current
obvious
focu
intens
research
although
certain
number
preclin
studi
involv
lysosom
regul
conduct
year
small
number
lysosometarget
therapeut
far
move
clinic
develop
one
biggest
advanc
develop
strategi
would
identif
genet
signatur
would
allow
patient
like
respond
specif
therapi
select
howev
stage
knowledg
specif
lysosomedirect
drug
intrins
lysosom
failur
genet
featur
might
predict
potenti
respond
still
lack
except
lsd
investig
requir
achiev
level
knowledg
obvious
also
depend
type
diseas
heterogen
frequenc
anoth
issu
associ
develop
lysosometarget
therapeut
relat
deliveri
use
nanovector
repres
attract
deliveri
method
owe
particular
uniqu
abil
penetr
across
cell
barrier
via
endolysosom
pathway
preferenti
home
organel
lysosom
sever
nanoscal
galen
form
develop
serv
vector
carrier
protein
peptid
nucleic
acid
vast
literatur
describ
mani
advantag
use
nanostructur
nanomedicin
howev
safeti
concern
carbon
nanostructur
claim
induc
nanotox
accompani
induct
autophagi
lysosom
review
purpos
review
gain
awar
import
lysosom
diseas
encourag
develop
novel
lysosom
target
drug
howev
research
need
character
compon
specif
link
lysosom
clearli
defin
specif
involv
lysosom
biogenesi
metabol
special
attent
given
mode
administr
lysosometarget
medic
order
minim
toxic
promot
specif
target
hope
larg
field
therapeut
applic
could
emerg
investig
encompass
rare
common
autoimmun
neurodegen
metabol
diseas
well
cancer
senesc
age
